Capital News

Intrahepatic Cholangiocarcinoma Pipeline | 20+ Key Players & 20+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

 Breaking News
  • No posts were found

Intrahepatic Cholangiocarcinoma Pipeline | 20+ Key Players & 20+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

November 23
22:25 2022
Intrahepatic Cholangiocarcinoma Pipeline | 20+ Key Players & 20+ Pipeline Drugs | FDA, EMA, and PMDA Approvals, Clinical Trials

DelveInsight’s, “Intrahepatic Cholangiocarcinoma Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Intrahepatic Cholangiocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Insight Report

  • DelveInsight’s Intrahepatic Cholangiocarcinoma Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Intrahepatic Cholangiocarcinoma treatment.
  • The major Intrahepatic Cholangiocarcinoma companies include Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences,  Siranomics, Instylla, Inc. and others are currently working to improve the Intrahepatic Cholangiocarcinoma treatment landscape.
  • Key Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib,  XmAb®22841, STP705,  Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009 and others.
  • The Intrahepatic Cholangiocarcinoma Companies and academics are working to assess challenges and seek opportunities that could influence Intrahepatic Cholangiocarcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Intrahepatic Cholangiocarcinoma.

 

Recent Developmental Activities in the Intrahepatic Cholangiocarcinoma Pipeline

  • TYRA-200, an FGFR2 inhibitor with an initial focus on patients with intrahepatic cholangiocarcinoma being developed by Tyra Biosciences. TYRA remains on track to submit an IND with the US FDA TYRA-200 in the second half of 2022.
  • In September 2021, Knight Therapeutics entered into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America. Under the terms of the agreement, Incyte will be responsible for the development, manufacture and supply to Knight of tafasitamab and pemigatinib, and Knight will be responsible for seeking the necessary regulatory approvals and distributing both medicines in Latin America.
  • In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.
  • In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trial in China.
  • Relay Therapeutics announced the initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008, an FGFR2-altered intrahepatic cholangiocarcinomain January 2022.
  • In May 2021, Kinnate Biopharma Inc. Closes USD 35 Million Series A Financing to Establish a Chinese Joint Venture. The joint venture will pursue the development of KIN-3248 for the Chinese market. KIN-3248 is a Fibroblast Growth Factor Receptors (FGFR) inhibitor candidate for the treatment of patients with intrahepatic cholangiocarcinoma (ICC).
  • In 2022, Basilea will continue its activities in oncology in order to ensure project continuity and progression. For derazantinib, the company will focus on continuing the FIDES-01 study in intrahepatic cholangiocarcinoma (iCCA).

 

Request a sample and discover the recent breakthroughs happening Intrahepatic Cholangiocarcinoma pipeline landscape @ Intrahepatic Cholangiocarcinoma Pipeline Outlook

 

Intrahepatic Cholangiocarcinoma Overview

Intrahepatic Cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

 

Intrahepatic Cholangiocarcinoma Emerging Drugs

Derazantinib: Basilea Pharmaceutica

Derazantinib is an orally administered small molecule inhibitor of the fibroblast growth factor receptor (FGFR) family of kinases. Derazantinib is currently in a registrational phase 2 study inIntrahepatic cholangiocarcinoma (iCCA). In January 2019, Basilea reported results from an interim analysis from this study. The efficacy results were encouraging and the analysis also confirmed the safety profile and tolerability of derazantinib observed in previous clinical studies.

Durvalumab: AstraZeneca

Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.

 

Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Analysis

There are approx. 20+ key companies which are developing the therapies for Intrahepatic Cholangiocarcinoma. The companies which have their Intrahepatic Cholangiocarcinoma drug candidates in the most advanced stage, i.e. phase II include, Basilea Pharmaceutica.

 

There are many factors affecting the Intrahepatic Cholangiocarcinoma prognosis. Find out these @ Intrahepatic Cholangiocarcinoma Treatment Landscape

 

Intrahepatic Cholangiocarcinoma Pipeline Therapeutics Assessment

The Intrahepatic Cholangiocarcinoma Pipeline report proffers an integral view of the Intrahepatic Cholangiocarcinoma emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

 

Intrahepatic Cholangiocarcinoma Pipeline Report Assessment

  • Intrahepatic Cholangiocarcinoma Pipeline Product Profiles
  • Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment
  • Intrahepatic Cholangiocarcinoma Pipeline Assessment
  • Intrahepatic Cholangiocarcinoma Inactive drugs assessment
  • Intrahepatic Cholangiocarcinoma Unmet Needs

 

Learn more about the novel and emerging Intrahepatic Cholangiocarcinoma pipeline therapies @ Intrahepatic Cholangiocarcinoma Clinical Trials

 

Scope of the Intrahepatic Cholangiocarcinoma Pipeline Report 

  • Coverage: Global 
  • Intrahepatic Cholangiocarcinoma Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Intrahepatic Cholangiocarcinoma Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Intrahepatic Cholangiocarcinoma Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravenous
  • Intrahepatic Cholangiocarcinoma Therapeutics Assessment By Molecule Type: Gene therapy, Small molecule, Polymers, Peptides, Monoclonal antibodies
  • Intrahepatic Cholangiocarcinoma Therapeutics Assessment By Mechanism of Action: Fibroblast growth factor receptor antagonists, Interleukin-12 and 15 expression stimulants, Toll-like receptor 9 agonists, Isocitrate dehydrogenase 1 inhibitors, Type 2 and 3 fibroblast growth factor receptor antagonists, Type-2 fibroblast growth factor receptor antagonists, Antibody-dependent cell cytotoxicity, Programmed cell death-1 receptor antagonists, T lymphocyte stimulants
  • Key Intrahepatic Cholangiocarcinoma Companies: Basilea Pharmaceutica, AstraZeneca, Delcath Systems Inc., Jiangsu HengRui Medicine Co., Ltd., Syndax Pharmaceuticals, Hutchison Medipharma Limited, Medivir, Newish Technology (Beijing) Co., Ltd., Relay Therapeutics, Inc., Exelixis, Forma Therapeutics, Inc., Xencor, Inc., Zymeworks, RedHill Biopharma Limited, Genoscience Pharma, Kinnate Biopharma, Taiho Oncology, Inc., Sirtex Medical, Virogin Biotech Ltd, TriSalus Life Sciences, Tyra Biosciences,  Siranomics, Instylla, Inc. and others.
  • Key Intrahepatic Cholangiocarcinoma Pipeline Therapies: Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib,  XmAb®22841, STP705,  Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009 and others.

 

Table of Content

  1. Introduction
  2. Intrahepatic Cholangiocarcinoma Executive Summary
  3. Intrahepatic Cholangiocarcinoma: Overview
  4. Intrahepatic Cholangiocarcinoma Pipeline Therapeutics
  5. Intrahepatic Cholangiocarcinoma Therapeutic Assessment
  6. Late Stage Products (Phase II/III)
  7. Melphalan/HDS: Delcath Systems
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. Derazantinib: Basilea Pharmaceutica
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I) 
  13. RLY-4008: Relay Therapeutics
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products 
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Intrahepatic Cholangiocarcinoma Key Companies
  20. Intrahepatic Cholangiocarcinoma Key Products
  21. Intrahepatic Cholangiocarcinoma- Unmet Needs
  22. Intrahepatic Cholangiocarcinoma- Market Drivers and Barriers
  23. Intrahepatic Cholangiocarcinoma- Future Perspectives and Conclusion
  24. Intrahepatic Cholangiocarcinoma Analyst Views
  25. Intrahepatic Cholangiocarcinoma Key Companies
  26. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Intrahepatic Cholangiocarcinoma drugs?
  • How many Intrahepatic Cholangiocarcinoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Intrahepatic Cholangiocarcinoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Intrahepatic Cholangiocarcinoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Intrahepatic Cholangiocarcinoma and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For further information on the Intrahepatic Cholangiocarcinoma pipeline therapeutics, reach out to Intrahepatic Cholangiocarcinoma Emerging Therapy

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/